Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.

Frank Jülhing , Nourdine Hamdane (1) , Emilie Crouchet (1) , Shen Li , Houssein El Saghire (1) , Atish Mukherji (1) , Naoto Fujiwara , Marine A. Oudot (1) , Christine Thumann (1) , Antonio Saviano (1) , Armando Andres Roca Suarez (1) , Kaku Goto (1) , Ricard Masia , Mozhdeh Sojoodi , Gunisha Arora , Hiroshi Aikata , Atsushi Ono , Parissa Tabrizian , Myron Schwartz , Stephen J Polyak , Irwin Davidson (2, 3, 4) , Christian Schmidl , Christoph Bock , Catherine Schuster (1) , Kazuaki Chayama , Patrick Pessaux (1) , Kenneth K Tanabe , Yujin Hoshida , Mirjam Zeisel (1) , Francois Ht Duong (1) , Bryan C Fuchs , Thomas Baumert (1)

1 IVH - Institut de Recherche sur les Maladies Virales et Hépatiques
2 IGBMC - Institut de génétique et biologie moléculaire et cellulaire
3 Inserm U964 - CNRS UMR7104 - IGBMC - Centre for Integrative Biology - CBI
4 IGBMC - Institut de Génétique et de Biologie Moléculaire et Cellulaire

Hepatocellular carcinoma (HCC) is the fastest-growing cause of cancer-related mortality with chronic viral hepatitis and non-alcoholic steatohepatitis (NASH) as major aetiologies. Treatment options for HCC are unsatisfactory and chemopreventive approaches are absent. Chronic hepatitis C (CHC) results in epigenetic alterations driving HCC risk and persisting following cure. Here, we aimed to investigate epigenetic modifications as targets for liver cancer chemoprevention.

Mots clés: chemoprevention gene expression hepatitis C hepatocellular carcinoma non-alcoholic steatohepatitis

Domaines: Médecine humaine et pathologie

Frank Jülhing, Nourdine Hamdane, Emilie Crouchet, Shen Li, Houssein El Saghire, et al.. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.. Gut, 2020, ⟨10.1136/gutjnl-2019-318918⟩. ⟨hal-02916776⟩